Cell-of-origin chromatin organization shapes the mutational landscape of cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
An analysis of cell-type-specific epigenomic features reveals a relationship between epigenomic and mutational profiles; chromatin characteristics can explain a large proportion of mutational variance in cancer genomes and the mutational distribution can identify the probable cell type from which a given cancer originated from. Genomic studies have shown that different cancer types vary substantially in the local density and types of somatic mutations. This has been explained not only by differences in DNA sequence but also by other features including epigenetic organization. Shamil Sunyaev and colleague now compare mutation densities to detailed epigenetic profiles of different cell types and tissues. They demonstrate that epigenomic features of a given cell type or tissue in which a cancer arises are much stronger determinants of mutational profiles than other properties. Conversely, the findings make it possible to deduce information on the possible tissue-of-origin of a tumour based on its mutational landscape. Cancer is a disease potentiated by mutations in somatic cells. Cancer mutations are not distributed uniformly along the human genome. Instead, different human genomic regions vary by up to fivefold in the local density of cancer somatic mutations1, posing a fundamental problem for statistical methods used in cancer genomics. Epigenomic organization has been proposed as a major determinant of the cancer mutational landscape1,2,3,4,5. However, both somatic mutagenesis and epigenomic features are highly cell-type-specific6,7. We investigated the distribution of mutations in multiple independent samples of diverse cancer types and compared them to cell-type-specific epigenomic features. Here we show that chromatin accessibility and modification, together with replication timing, explain up to 86% of the variance in mutation rates along cancer genomes. The best predictors of local somatic mutation density are epigenomic features derived from the most likely cell type of origin of the corresponding malignancy. Moreover, we find that cell-of-origin chromatin features are much stronger determinants of cancer mutation profiles than chromatin features of matched cancer cell lines. Furthermore, we show that the cell type of origin of a cancer can be accurately determined based on the distribution of mutations along its genome. Thus, the DNA sequence of a cancer genome encompasses a wealth of information about the identity and epigenomic features of its cell of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutation rates vary in different parts of the genome, at different stages of the life cycle and in diseases such as cancer, where they depend on the cell of origin, environmental exposure and cancer type [60][61][62] .”
From Advances in epigenetics link genetics to the environment and disease (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPermutation importance: a corrected feature importance measure
Altmann, A., Toloşi, L., Sander, O., & Lengauer, T. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq134 · Cited by 2,843
The accessible chromatin landscape of the human genome
Thurman, R. E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M. T., Haugen, E., Sheffield, N. C., Stergachis, A. B., Wang, H., Vernot, B., et al. (2012) · Nature · doi:10.1038/nature11232 · Cited by 2,679
Self-citation
Cited by
Items 501–548 of 548
Abdalla, O., & Walker, C. G. (2024) · Research Square · doi:10.21203/rs.3.rs-4342402/v3
Sandoval, G. J., Gioacchini, N., Wu, L., Kalogeropulou, A. F., Hesler, S. J., Taherbhoy, A. M., Netherton, M. R., Bellon, S. F., & Daniels, D. L. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00473
Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets
(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part3
Emerging Technologies for Epigenetic Drug Discovery
(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part2
Enterale Inflammation und Tumorgenese: Differenzierte Zellen als Quelle kolorektaler Karzinome
Schmitt, M. (2025) · Deutsches Ärzteblatt · doi:10.3238/persgastro.2025.04.04.03
Damage and Misrepair Signatures: Compact Representations of Pan-cancer Mutational ProcessesPreprint
Harrigan, C. F., Campbell, K. R., Morris, Q., & Funnell, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.29.656360
“It is therefore dif fi cult for SBS signature analyses to isolate the contributions of individual damage or misrepair process activities 13,17,24 .”
Advances in epigenetic techniques to study development and diseases
Dzobo, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26759-8.00019-9
Additional file 1 of MutationalPatterns: the one stop shop for the analysis of mutational processes
Manders, F., Brandsma, A. M., de Kanter, J. K., Verheul, M., Oka, R., van Roosmalen, M. J., der Roest, B. R. V., van Hoeck, A., Cuppen, E. P. J. G., & van Boxtel, R. (2022) · Figshare · doi:10.6084/m9.figshare.19220881
Meyerson, W., Leisman, J., Navarro, F. C. P., & Gerstein, M. (2020) · Figshare · doi:10.6084/m9.figshare.12432275
Zhang, J., Liu, J. J., McGillivray, P. D., Yi, C., Lochovsky, L., Lee, D., & Gerstein, M. (2020) · Figshare · doi:10.6084/m9.figshare.13141970
Vu, H., & Ernst, J. (2022) · Figshare · doi:10.6084/m9.figshare.17982268
Additional file 2 of MutationalPatterns: the one stop shop for the analysis of mutational processes
Manders, F., Brandsma, A. M., de Kanter, J. K., Verheul, M., Oka, R., van Roosmalen, M. J., der Roest, B. R. V., van Hoeck, A., Cuppen, E. P. J. G., & van Boxtel, R. (2022) · Figshare · doi:10.6084/m9.figshare.19220884
Vu, H., & Ernst, J. (2022) · Figshare · doi:10.6084/m9.figshare.17982259
Meyerson, W., Leisman, J., Navarro, F. C. P., & Gerstein, M. (2020) · Figshare · doi:10.6084/m9.figshare.12432284
Meyerson, W., Leisman, J., Navarro, F. C. P., & Gerstein, M. (2020) · Figshare · doi:10.6084/m9.figshare.12432269
Lee, C. A., Abd-Rabbo, D., & Reimand, J. (2021) · Figshare · doi:10.6084/m9.figshare.14532252
Additional file 3 of MutationalPatterns: the one stop shop for the analysis of mutational processes
Manders, F., Brandsma, A. M., de Kanter, J. K., Verheul, M., Oka, R., van Roosmalen, M. J., der Roest, B. R. V., van Hoeck, A., Cuppen, E. P. J. G., & van Boxtel, R. (2022) · Figshare · doi:10.6084/m9.figshare.19220887
Assante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., Banks, J. L., Soffientini, U., Filippi, C., Dhawan, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20153143
Lee, C. A., Abd-Rabbo, D., & Reimand, J. (2021) · Figshare · doi:10.6084/m9.figshare.14532258
Meyerson, W., Leisman, J., Navarro, F. C. P., & Gerstein, M. (2020) · Figshare · doi:10.6084/m9.figshare.12432260
Abdollahi, S., Dehghanian, S. Z., Hung, L.-Y., Yang, S.-J., Chen, D.-P., Medeiros, L. J., Chiang, J.-H., & Chang, K.-C. (2021) · Figshare · doi:10.6084/m9.figshare.16786653
Sanjaya, P., Maljanen, K., Katainen, R., Waszak, S. M., Aaltonen, L. A., Stegle, O., Korbel, J. O., & Pitkänen, E. (2023) · Figshare · doi:10.6084/m9.figshare.23647585
Vu, H., & Ernst, J. (2022) · Figshare · doi:10.6084/m9.figshare.17982253
Vu, H., & Ernst, J. (2022) · Figshare · doi:10.6084/m9.figshare.17982292
Sanjaya, P., Maljanen, K., Katainen, R., Waszak, S. M., Aaltonen, L. A., Stegle, O., Korbel, J. O., & Pitkänen, E. (2023) · Figshare · doi:10.6084/m9.figshare.23647582
Jordà, M., Díez-Villanueva, A., Mallona, I., Martín, B., Olmo, S. L., Barrera, V., Esteller, M., Vavouri, T., & Morales, M. Á. (. Á. P. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 17
Noguchi, G., Baba, M., Ohtake, S., Jikuya, R., Mitome, T., Kawaura, S., Aomori, K., Iribe, Y., Nagasaka, H., Krisna, L. A. W., et al. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0043 · Cited by 1
Vasanthakumari, P., Valencia, I., Omar, M. A., & Ince, T. A. (2026) · medRxiv · doi:10.64898/2026.01.31.26345244
Predicting mutation-rate variation across the genome using epigenetic dataPreprint
Katori, M., Kobayashi, T. J., Nordborg, M., & Shi, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702885
“Yet CDS-level epigenetic patterns can be partially obscured by chro-63 matin organization [3, 4, 16] and broad chromatin-state annotations (e.g., ChromHMM) [17, 18, 19].”
遺伝子変異に対する H3K9 メチル化ヘテロクロマチンの影響を調査する新しい方法
Abdalla, O. (2024) · Institutional Repositories DataBase (IRDB) · doi:10.14943/doctoral.k16137
Silent chromatin dynamics upon major metabolic transitions
Guidi, M. (2015) · theses.fr (ABES) · doi:10.70675/bca89b62z04abz4a8dzb827z0ec81fda2b70
Structure de la chromatine et éléments transposables : une approche évolutive
Barbier, J. (2022) · theses.fr (ABES) · doi:10.70675/dd1ee9e6z52fez46d7za781ze5573e9c1277
Identification and characterization of key epigenetic drivers of breast cancer
Araujo, M. G. D. S. (2024) · theses.fr (ABES) · doi:10.70675/de1e1ca7zb3fez4d95za929z354256240e6e
Epigenetic characterization of cellular pliancy in breast cancer
Benhassoun, R. (2024) · theses.fr (ABES) · doi:10.70675/0b1d39b2za3d7z4b26zb4b0zaafa77d5068a
Non-genetic regulation of chemopersistence in Triple Negative Breast Cancers
Baudre, L. (2024) · theses.fr (ABES) · doi:10.70675/6422f0bbza832z4dcfza920zaa55605f8a31
Alba‐Linares, J. J., Tejedor, J. R., Sainz‐Ledo, L., Fernández, A. F., Pérez, R. F., & Fraga, M. F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721644
“…including aberrant chromosomal translocations, structural abnormalities, and illegitimate recombination of repetitive elements (77– 79), whereas heterochromatin spreading associates with cell differentiation (80), phenotypic transcriptional plasticity (81), and elevated mutation rates (82, 83).”
Why are Some Tissues More Vulnerable? Revisiting Tissue Specificity in Hereditary Cancer Syndromes
Kozak, V. N., de Oliveira, J. C., Gradia, D. F., Mathias, C., & Ribeiro, E. M. S. F. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00845-6
“…the mutational profile to the same extent as chromatin features of the normal cells of origin, which rises up the possibility that most somatic mutations in cancer are defined by the epigenomic profile of the cell of origin, and not by epigenetic changes linked to the neo-plastic progression [80].”
Jiang, H., Bahcheli, A. T., Cheng, K. C. L., & Reimand, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.24.727503
“Earlier studies showed that large-scale chromatin organization is associated with mutation rates at broad genomic scales, and that cell-of-origin CA shapes regional mutational landscapes across cancer types 20,23 .”
InfluentialThe Channelled Substrate: Physical Constraints on Biological VariationPreprint
Goel, S. S. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6916240
Verhagen, M. P., Guerra, E. M., Joosten, R., Sacchetti, A., Sun, W., Lila, K. A., Nigg, A. L., Ahmed, E. I., Saadeh, H., van den Bosch, T. P. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733748
“…CRCs. Finally, we took advantage of whole-genome sequencing data from a cohort of n=165 sporadic colorectal cancers 5 and computed cell-of-origin predictions based on the association between mutational spectra and epigenetic profiles of distinct cell lineages, as previously shown 2,31,32 (Suppl.”
Ioramashvili, I., Gogebashvili, M., Sujashvili, R., & Ivanishvili, N. (2026) · Radiobiology and Radiation Safety · doi:10.63465/rrs6202611763
Zheng, W., Yu, L., Wu, C., Cao, S., Zhao, M., Wang, G., So, K. H., Song, J., Chen, C., Ho, J. W. K., et al. (2026) · Genome biology · doi:10.1186/s13059-026-04211-x
“The precise control of potential editing outcomes is often required in a wide range of derived applications, including generating model animals, treating genetic diseases by correcting pathogenic genetic variations, and engineering therapeutic cells [4–6].”
Determinants of mutation susceptibility along the genome are largely invariant across human tissues
Schmalohr, C. L., Paul, Y., Bundschuh, N., & Beyer, A. (2026) · Genome biology · doi:10.1186/s13059-026-04245-1
“At megabase resolution, 55–86% of variance can be explained [10, 11].”
Replicative history as a major determinant of epigenetic noise across human tissuesPreprint
Peñarroya, A., Alba‐Linares, J. J., Pérez, R. F., Fernández, A. F., Fraga, M. F., & Tejedor, J. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.19.745715
“Instead, they are strongly influenced by genomic context and sequence-associated factors, as also observed for mutations[40].”
Li, J., & Xu, W. (2026) · Research Square · doi:10.21203/rs.3.rs-10849752/v1
Freudenberger, S., Boczko, E., Goel, S., & Maitra, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.28.754892
“It has been established that cancer mutations are not randomly distributed throughout the human genome, rather are statistically found at higher rates at specific points in the sequence, leading to known hotspots [2].”
Delocalized DNA holes imprint mutation position in mismatch-repair-deficient cancersPreprint
Sung, J., & Cheong, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.14.759081
Metadata
- Authors
- Polak, P., Karlić, R., Koren, A., Thurman, R., Sandstrom, R., Lawrence, M. S., Reynolds, A., Rynes, E., Vlahoviček, K., Stamatoyannopoulos, J. A., & Sunyaev, S. R.
- Affiliations
- Broad Institute (US)
- University of Zagreb (HR)
- University of Washington (US)
- Corresponding author
- Stamatoyannopoulos, John A.
- Sunyaev, Shamil R.
- ORCID
- Venue
- Nature
- Published
- 2015-02-18
- Volume
- 518
- Issue
- 7539
- Pages
- 360-364
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4405175
- OpenAlex
- W2086239585
- Cited by
- 557
- References
- 29
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 41 · 2023: 41 · 2022: 46 · 2021: 56 · 2020: 55 · 2019: 62 · 2018: 46 · 2017: 60 · 2016: 65 · 2015: 29
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (HL53750)
- National Heart, Lung, and Blood Institute (P01HL053750, P01 HL53750)
- National Institute of Mental Health (R01MH101244)
- National Human Genome Research Institute (U54HG007010)
- National Cancer Institute (U54CA143874)
- National Institute of Environmental Health Sciences (U01ES017156)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- cell of origin, chromatin accessibility, chromatin modification, DNA replication timing, somatic mutations, mutation density, tissue of origin prediction, cancer cell lines
- MeSH terms
- Chromatin, Humans, Melanocytes, Melanoma, Mutation, Neoplasms, Organ Specificity, Genome, Human, DNA Replication Timing, Epigenesis, Genetic, Cell Line, Tumor, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.